159 related articles for article (PubMed ID: 12792748)
1. Hypermethylation of the CDKN2A gene in colorectal cancer is associated with shorter survival.
Maeda K; Kawakami K; Ishida Y; Ishiguro K; Omura K; Watanabe G
Oncol Rep; 2003; 10(4):935-8. PubMed ID: 12792748
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation of the MYOD1 gene is a novel prognostic factor in patients with colorectal cancer.
Hiranuma C; Kawakami K; Oyama K; Ota N; Omura K; Watanabe G
Int J Mol Med; 2004 Mar; 13(3):413-7. PubMed ID: 14767572
[TBL] [Abstract][Full Text] [Related]
3. Influence of methylated p15 and p16 genes on clinicopathological features in colorectal cancer.
Ishiguro A; Takahata T; Saito M; Yoshiya G; Tamura Y; Sasaki M; Munakata A
J Gastroenterol Hepatol; 2006 Aug; 21(8):1334-9. PubMed ID: 16872319
[TBL] [Abstract][Full Text] [Related]
4. Aberrant methylation of the p16 gene is frequently detected in advanced colorectal cancer.
Goto T; Mizukami H; Shirahata A; Sakata M; Saito M; Ishibashi K; Kigawa G; Nemoto H; Sanada Y; Hibi K
Anticancer Res; 2009 Jan; 29(1):275-7. PubMed ID: 19331161
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of p16INK4a by CpG hypermethylation is not a frequent event in colorectal cancer.
Norrie MW; Hawkins NJ; Todd AV; Meagher AP; O'Connor TW; Ward RL
J Surg Oncol; 2003 Nov; 84(3):143-50. PubMed ID: 14598358
[TBL] [Abstract][Full Text] [Related]
6. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer.
Ogino S; Hazra A; Tranah GJ; Kirkner GJ; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Meyerhardt JA; Hunter DJ; Fuchs CS
Carcinogenesis; 2007 Sep; 28(9):1985-90. PubMed ID: 17621591
[TBL] [Abstract][Full Text] [Related]
7. CDKN2A promoter methylation in gastric adenocarcinomas: clinical variables.
Vo QN; Geradts J; Boudreau DA; Bravo JC; Schneider BG
Hum Pathol; 2002 Dec; 33(12):1200-4. PubMed ID: 12514789
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of tumor-related genes in peritoneal lavage and the prognosis of patients with colorectal cancer.
Kamiyama H; Noda H; Takata O; Suzuki K; Kawamura Y; Konishi F
J Surg Oncol; 2009 Jul; 100(1):69-74. PubMed ID: 19384904
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis.
Kawaguchi K; Oda Y; Saito T; Yamamoto H; Tamiya S; Takahira T; Miyajima K; Iwamoto Y; Tsuneyoshi M
J Pathol; 2003 Nov; 201(3):487-95. PubMed ID: 14595762
[TBL] [Abstract][Full Text] [Related]
10. The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases.
Ai L; Stephenson KK; Ling W; Zuo C; Mukunyadzi P; Suen JY; Hanna E; Fan CY
Mod Pathol; 2003 Sep; 16(9):944-50. PubMed ID: 13679459
[TBL] [Abstract][Full Text] [Related]
11. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation and quantitative expression analysis of CDKN2A (p14ARF and p16INK4a) gene in esophageal squamous cell carcinoma.
Ito S; Ohga T; Saeki H; Watanabe M; Kakeji Y; Morita M; Yamada T; Maehara Y
Anticancer Res; 2007; 27(5A):3345-53. PubMed ID: 17970080
[TBL] [Abstract][Full Text] [Related]
13. Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features.
Lin SY; Yeh KT; Chen WT; Chen HC; Chen ST; Chiou HY; Chang JG
Oncol Rep; 2004 Feb; 11(2):341-8. PubMed ID: 14719065
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines.
Ku JL; Kang SB; Shin YK; Kang HC; Hong SH; Kim IJ; Shin JH; Han IO; Park JG
Oncogene; 2004 Sep; 23(40):6736-42. PubMed ID: 15273736
[TBL] [Abstract][Full Text] [Related]
15. p16 Gene methylation in colorectal tumors: correlation with clinicopathological features and prognostic value.
Sanz-Casla MT; Maestro ML; Vidaurreta M; Maestro C; Arroyo M; Cerdán J
Dig Dis; 2005; 23(2):151-5. PubMed ID: 16352895
[TBL] [Abstract][Full Text] [Related]
16. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications.
González-Quevedo R; García-Aranda C; Morán A; De Juan C; Sánchez-Pernaute A; Torres A; Díaz-Rubio E; Balibrea JL; Benito M; Iniesta P
Int J Oncol; 2004 Feb; 24(2):349-55. PubMed ID: 14719111
[TBL] [Abstract][Full Text] [Related]
17. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation of the GATA genes in lung cancer.
Guo M; Akiyama Y; House MG; Hooker CM; Heath E; Gabrielson E; Yang SC; Han Y; Baylin SB; Herman JG; Brock MV
Clin Cancer Res; 2004 Dec; 10(23):7917-24. PubMed ID: 15585625
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis.
Umetani N; Takeuchi H; Fujimoto A; Shinozaki M; Bilchik AJ; Hoon DS
Clin Cancer Res; 2004 Nov; 10(22):7475-83. PubMed ID: 15569977
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
